Expression of defensin related proteins in cancers of head and neck
Not Applicable
- Conditions
- Health Condition 1: C00-C14- Malignant neoplasms of lip, oral cavity and pharynxHealth Condition 2: C00-D49- Neoplasms
- Registration Number
- CTRI/2020/06/026066
- Lead Sponsor
- AIIMS Jodhpur
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients of head and neck cancers during the study period
Exclusion Criteria
Patients with known mutation diagnosed tumour syndromes of pre confirmed familial cancer syndromes will be excluded as their molecular progression is already established. Patients not consenting for the study will also be excluded.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Expression of Human Beta defensin 1 <br/ ><br>and <br/ ><br>expression of human beta defensin 3Timepoint: 1st year 15 TO 20 cases <br/ ><br>2nd year 15 TO 20 cases
- Secondary Outcome Measures
Name Time Method relative expression of HBD1 and HBD3 AND CORRELATION OF RATIO OF hbd EXPRESSION TO THE CLINICAL AND HISTOLOGICAL FEATURES.Timepoint: 1st year 15 TO 20 cases <br/ ><br>2nd year 15 TO 20 cases <br/ ><br>